Engineered calprotectin-sensing probiotics for IBD surveillance in humans
Abstract
Inflammatory bowel disease (IBD) is a spectrum of autoimmune diseases affecting the gastrointestinal tract characterized by a relapsing and remitting course of gut mucosal inflammation. Disease flares can be difficult to predict, and the current practice of IBD disease activity surveillance through endoscopy is invasive and requires medical expertise. Recent advancements in synthetic biology raise the possibility that symbiotic microbes can be engineered to selectively detect disease biomarkers used in current clinical practice. Here, we introduce an engineered probiotic capable of detecting the clinical gold standard IBD biomarker, calprotectin, with sensitivity and specificity in IBD patients. Specifically, we identified a bacterial promoter in the probiotic strain Escherichia coli Nissle 1917 (EcN) which exhibits a specific expression increase in the presence of calprotectin. Using murine models of colitis, we show that the reporter signal is activated in vivo during transit of the GI tract following oral delivery. Furthermore, our engineered probiotic can successfully discriminate human patients with active IBD from those in remission and without IBD using patient stool samples, where the intensity of reporter signal quantitatively tracks with clinical laboratory–measured levels of calprotectin. Our pilot study sets the stage for probiotics that can be engineered to detect fecal calprotectin for precise noninvasive disease activity monitoring in IBD patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 31, 2023
- Source ID
- 10.1073/pnas.2221121120
Entities
People
- Arthur Prindle
- Chelsea Hepler
- Jonathan Y. Xia
- Joseph Bass
- Nathan J. Waldeck
- Peter Tran
Organizations
- Army Research Office
- Burroughs Wellcome Fund
- David and Lucile Packard Foundation
- Northwestern University
- The Pew Charitable Trusts